FLC
XERS icon

Fifth Lane Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Fifth Lane Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,513
Closed -$45K – 381
2022
Q1 		$45K Buy
+17,513
New +$42.8K 0.03% 176

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fifth Lane Capital's XERS Position: Q2 2022 in Review

Fifth Lane Capital sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 17,513 shares — an estimated $45K sold.

Fifth Lane Capital first reported a position in XERS in Q1 2022 and held it in 1 quarter. The position peaked at $45K in Q1 2022. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

  • Fifth Lane Capital reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
  • Fifth Lane Capital sold 17,513 Xeris Biopharma Holdings shares in Q2 2022, an estimated $45K.
  • Fifth Lane Capital first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 1 quarter.
  • Fifth Lane Capital's Xeris Biopharma Holdings position peaked at $45K in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on Fifth Lane Capital's 13F filing for Q2 2022, filed 15 Aug 2022.